[Market Focus] Samyang Biopharm Hits Upper Price Limit on First Trading Day
Samyang Biopharm, the pharmaceutical and biotechnology subsidiary of Samyang Group, hit the upper price limit on its first day of trading on the Korea Exchange following a spin-off.
As of 10:50 a.m. on November 24, Samyang Biopharm was trading at 30,200 won, up 29.89% from its opening price.
![[Market Focus] Samyang Biopharm Hits Upper Price Limit on First Trading Day](http://www.asiae.co.kr/news/img_view.htm?img=2025112410570628891_1763949426.jpg)
This listing was carried out through a direct listing method after being spun off from Samyang Holdings, the holding company of Samyang Group. The total number of listed shares is 7,435,870.
Hot Picks Today
"I Wish I Could Sleep": Frozen Meals, Two Hours...
- The Quoted 800,000 Won, the Bill Was 5 Million... Bereaved Families of 'No-Funer...
- "You Can Only Have This in Korea": Which National Museum Cafe Menu Is Captivatin...
- Tragedy in Luxury Apartment: Woman in Her 20s Found Dead, Suspect Identified
- "Never Hike Alone as a Woman" "Even Two Are at Risk"... Growing Fear of Crime on...
As an independent corporation specializing in pharmaceutical and biotechnology businesses, Samyang Biopharm plans to strengthen its global competitiveness by focusing on high-performance bio products such as biodegradable surgical sutures, gene delivery systems, and anticancer drugs.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
